{'52WeekChange': -0.69616026,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Parc EurasantE',
 'address2': '885, Avenue EugEne AvinEe',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.43,
 'askSize': 1100,
 'averageDailyVolume10Day': 45825,
 'averageVolume': 133922,
 'averageVolume10days': 45825,
 'beta': 0.887209,
 'beta3Year': None,
 'bid': 5.37,
 'bidSize': 1400,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Loos',
 'companyOfficers': [],
 'country': 'France',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.49,
 'dayLow': 5.3605,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 212069056,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '33 2 20 16 40 01',
 'fiftyDayAverage': 5.6652856,
 'fiftyTwoWeekHigh': 22.48,
 'fiftyTwoWeekLow': 5.1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 36917493,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 194,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.03368,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/genfit.com',
 'longBusinessSummary': 'Genfit SA, a biopharmaceutical company, develops '
                        'therapeutic and diagnostic solutions for metabolic, '
                        'inflammatory, autoimmune, and fibrotic diseases '
                        'affecting primarily the liver and gastroenterology. '
                        "The company's lead products include Elafibranor, "
                        'which is in pivotal Phase III clinical trials for the '
                        'treatment of nonalcoholic steatohepatitis (NASH), as '
                        'well as completed Phase II clinical trial to treat '
                        'patients with primary biliary cholangitis; and '
                        'Nitazoxanide that is in Phase II proof-of-concept '
                        'clinical trial for the treatment of NASH-induced '
                        'significant or severe fibrosis. It is also developing '
                        'in-vitro diagnostic tests for the identification of '
                        'patients with NASH; NIS4 for identifying patients '
                        'with NASH and fibrosis; and TGFTX1 preclinical '
                        'program for treating psoriasis or respiratory '
                        'conditions, such as neutrophilic asthma, chronic '
                        'obstructive pulmonary disease (COPD), and the '
                        'asthma-COPD overlap syndrome. Genfit SA was founded '
                        'in 1999 and is headquartered in Loos, France.',
 'longName': 'Genfit SA',
 'market': 'us_market',
 'marketCap': 215316192,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9683234',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.45,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '33 3 20 16 40 00',
 'previousClose': 5.49,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -1.67139,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.49,
 'regularMarketDayLow': 5.3605,
 'regularMarketOpen': 5.45,
 'regularMarketPreviousClose': 5.49,
 'regularMarketPrice': 5.45,
 'regularMarketVolume': 19627,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 38839600,
 'sharesPercentSharesOut': 0.0015,
 'sharesShort': 58344,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 82987,
 'shortName': 'GENFIT S.A.',
 'shortPercentOfFloat': None,
 'shortRatio': 0.61,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'GNFT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 13.127345,
 'volume': 19627,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.genfit.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '59120'}